The researchers calculated the risk of the participants’ cancer getting worse after
starting study treatment. They compared the risk between the participants who
took olaparib and those who took the NHA treatments.
The participants who took olaparib had a 66% reduced risk of their cancer getting
worse compared with the participants who took the NHA treatments.
The graph below shows the average number of months until the participants’
cancer got worse.
Average number of months until
the cancer got worse
10
esrow
9
8 7.4 tog
7 recnac
6 )shtnom(
eht
5
3.6 litnu
4
emit
3
2 egarevA
1
0
Olaparib NHA treatments
9 | Clinical Study Results